Renalytix Ai Plc-adr (RNLX)

$0.4381

Market is closed - opens 7 PM, 23 May 2024

Insights on Renalytix Ai Plc-adr

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 709.0K → 535.0K (in $), with an average decrease of 24.5% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 6 quarters, -12.10M → -7.74M (in $), with an average increase of 9.5% per quarter

  • Vs HQY

    In the last 1 year, Healthequity Inc has given 35.6% return, outperforming this stock by 114.9%

Performance

  • $0.42
    $0.45
    $0.44
    downward going graph

    3.86%

    Downside

    Day's Volatility :6.42%

    Upside

    2.65%

    downward going graph
  • $0.24
    $4.04
    $0.44
    downward going graph

    44.34%

    Downside

    52 Weeks Volatility :93.94%

    Upside

    89.11%

    downward going graph

Returns

PeriodRenalytix Ai Plc-adrSector (Health Care)Index (Russel 2000)
3 Months
-41.33%
-0.6%
0.0%
6 Months
-14.54%
12.1%
0.0%
1 Year
-79.26%
11.3%
0.0%
3 Years
-98.45%
17.6%
-20.1%

Highlights

Market Capitalization
43.6M
Book Value
- $0.08
Earnings Per Share (EPS)
-0.76
Wall Street Target Price
4.0
Profit Margin
0.0%
Operating Margin TTM
-1175.6%
Return On Assets TTM
-88.32%
Return On Equity TTM
-651.4%
Revenue TTM
2.4M
Revenue Per Share TTM
0.05
Quarterly Revenue Growth YOY
-40.5%
Gross Profit TTM
720.0K
EBITDA
-37.8M
Diluted Eps TTM
-0.76
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.34
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
-0.07
EPS Estimate Next Quarter
-0.07

Analyst Recommendation

Buy
    87%Buy
    12%Hold
    0
    0%Sell
Based on 8 Wall street analysts offering stock ratings for Renalytix Ai Plc-adr(by analysts ranked 0 to 5 stars)
Based on 8 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
7
7
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 813.03%

Current $0.44
Target $4.00

Technicals Summary

Sell

Neutral

Buy

Renalytix Ai Plc-adr is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Renalytix Ai Plc-adr
Renalytix Ai Plc-adr
-41.65%
-14.54%
-79.26%
-98.45%
-98.45%
Solventum Corp
Solventum Corp
-1.37%
-11.4%
-11.4%
-11.4%
-11.4%
Veeva Systems Inc.
Veeva Systems Inc.
5.11%
19.08%
26.56%
-20.38%
44.87%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
-2.81%
11.33%
3.62%
35.46%
35.46%
Healthequity Inc
Healthequity Inc
-2.32%
18.78%
35.6%
2.03%
13.46%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Renalytix Ai Plc-adr
Renalytix Ai Plc-adr
NA
NA
NA
-0.34
-6.51
-0.88
NA
-0.08
Solventum Corp
Solventum Corp
NA
NA
NA
6.26
0.17
0.08
NA
NA
Veeva Systems Inc.
Veeva Systems Inc.
65.41
65.41
1.35
4.76
0.13
0.05
NA
28.8
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
23.71
23.71
20.11
4.27
0.22
0.06
0.0
16.23
Healthequity Inc
Healthequity Inc
124.06
124.06
2.29
2.19
0.03
0.03
NA
23.63
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Renalytix Ai Plc-adr
Renalytix Ai Plc-adr
Buy
$43.6M
-98.45%
NA
0.0%
Solventum Corp
Solventum Corp
NA
$10.8B
-11.4%
NA
15.73%
Veeva Systems Inc.
Veeva Systems Inc.
Buy
$33.9B
44.87%
65.41
22.24%
Ge Healthcare Technologies Inc.
Ge Healthcare Technologies Inc.
Buy
$37.2B
35.46%
23.71
8.05%
Healthequity Inc
Healthequity Inc
Buy
$6.9B
13.46%
124.06
5.57%

Institutional Holdings

  • CVI Holdings LLC

    1.55%
  • Gilder Gagnon Howe & CO LLC

    1.19%
  • Pinnacle Associates Inc

    1.15%
  • Pentwater Capital Management LP

    0.95%
  • Tejara Capital Ltd

    0.54%
  • CI Private Wealth LLC

    0.45%

Corporate Announcements

  • Renalytix Ai Plc-adr Earnings

    Renalytix Ai Plc-adr’s price-to-earnings ratio stands at None

    Read More

Company Information

renalytix ai plc (lse aim: renx) is a leading developer of artificial intelligence-enabled clinical diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. the company’s solutions are being designed to make significant improvements in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. renalytixai’s initial diagnostic product, kidneyintelx™, is designed to diagnose and improve clinical management of patients with type ii diabetes and those of african ancestry with fast-progressing kidney disease in an effort to curtail the estimated $114 billion cost of chronic and end-stage kidney disease to the u.s. healthcare system. renalytixai expects to commercially launch kidneyintelx as a laboratory developed test in its clia laboratory facilities to health systems and drug developers in h2 2019. the company also intends to submit kidneyintelx for regulatory rev

Organization
Renalytix Ai Plc-adr
Employees
0
CEO
Mr. James R. McCullough M.B.A.
Industry
Technology Services

FAQs